TY - JOUR
AR - JCMCR-2020-2-106
TI - Cryptococcal Endocarditis in a Woman with Metastatic Non-Small Cell Lung Cancer: A Case Report and Review of the Literature
AU - Tony, Kurian
AU - Jason , Peng
AU - Courtney Regan , Wagner
AU - Fritzie S. , Albarillo
JO - Journal of Clinical and Medical Case Reports
PY - 2020
DA - Mon 27, Jul 2020
SN - 2733-2268
DO - http://dx.doi.org/10.31487/j.JCMCR.2020.02.06
UR - https://www.sciencerepository.org/cryptococcal-endocarditis-in-a-woman-with-metastatic-non-small-cell_JCMCR-2020-2-106 
KW - Cryptococcal endocarditis, cryptococcal meningitis, non-small cell lung cancer, tyrosine kinase inhibitor, erlotinib, targeted therapy
AB - Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated improved
progression-free survival benefits and decreased treatment-related side effects, and therefore are now
considered first-line of treatment of EGFR mutated, metastatic non-small cell lung carcinoma (NSCLC).
Cryptococcal endocarditis is an extremely rare clinical entity with only seven reported cases in the literature.
Prior cases were seen in patients with a history of rheumatic heart disease or prior valve replacement surgery.
Little is known regarding the natural history and optimal management of Cryptococcal endocarditis, given
the limited available data. We present a case of Cryptococcal endocarditis and meningitis in a patient with
metastatic NSCLC receiving targeted therapy with an EGFR-TKI with no history of significant cardiac
disease.